.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. Stephan Ludwig

Muenster / DE

University Muenster

Further involvements

28/03/2023
Poster
P 067
Variant-specific humoral immune response in an immunocompromised patient experiencing severe, prolonged SARS-CoV-2 infection complicated by escape mutants and self-limiting Omicron re-infection
Clinical virology
28/03/2023
Poster
P 068
Detection and differentiation of variant-specific antibodies against the SARS-CoV-2 spike protein using nanoluciferase-tagged RBD- and NTD-antigens in sVNT and capture EIA
Clinical virology
28/03/2023
Poster
P 234
The host-targeted MEK1/2-inhibitor ATR-002 (Zapnometinib) acts antiviral against SARS-CoV-2 and synergistically potentiates the antiviral effect of direct-acting anti-SARS-CoV-2 drugs
Host cell factors and modulation, SARS-CoV-2
28/03/2023
Poster
P 238
A virus-free reporter enzyme assay to identify antiviral drug candidates against SARS-CoV-2 spike protein mediated cell-cell fusion
Antiviral therapy and resistance, SARS-CoV-2
28/03/2023
Poster
P 036
Insights into the antiviral activity of Hypericum perforatum extract and its ingredient hypericin
Antiviral therapy and resistance, SARS-CoV-2
28/03/2023
Poster
P 186
Interference of host anti-viral factor Nicastrin with the assembly/budding of influenza A virus
Host cell factors and modulation, Structure, assembly, egress
28/03/2023
Poster
P 190
Immunomodulatory role of cellular p38 MAP kinase in Influenza virus and Streptococcus pneumoniae super-infection
Host cell factors and modulation, Innate immunity
30/03/2023
08:45 – 09:00 12 Min. 3 Min.
Abstract Talk
O 080
Cotreatment with Influenza inhibitors and recombinant IFNα as a potential strategy to prevent emergence of drug resistance against direct-acting antivirals
Antiviral therapy and resistance, Innate immunity
31/03/2023
11:15 – 11:30 12 Min. 3 Min.
Abstract Talk
O 105
Molecular characterisation of a 2017/18 clinical influenza B/Yamagata isolate reveals improved adaptation to the human lower respiratory tract
Viral pathogenesis and persistence, Viral replication strategies 1 (RNA viruses)